38 results about "Upper urinary tract" patented technology

A method of treating the upper urinary tract of a mammal having a urethra extending to a bladder and a ureter extending from the bladder to a kidney. The method comprises initially extending a catheter system into the upper urinary tract, the catheter system having a urethral catheter infusion tube section extending through the urethra for infusion of a liquid; a urethral catheter drain tube section extending through the urethra for drainage of a liquid; a ureteral catheter tube section extending through a ureter into the kidney and having a first tube portion for infusion of a liquid connected to the urethral catheter infusion tube section, and a second tube portion for drainage of a liquid. The method then includes flowing a therapeutically effective liquid into the kidney through the urethral catheter infusion tube section and the ureteral catheter first, infusion tube portion, and, simultaneously with the flowing of the fluid into the kidney, draining fluid from the kidney through the urethral catheter drain tube section and the ureteral catheter second, drain tube portion.

The invention provides devices, systems and methods for tissue approximation and repair at treatment sites. The devices, systems and methods of the invention will find use in a variety of therapeutic procedures, including endovascular, minimally-invasive, and open surgical procedures, and can be used in various anatomical regions, including the abdomen, thorax, cardiovascular system, heart, intestinal tract, stomach, urinary tract, bladder, lung, and other organs, vessels, and tissues. The invention is particularly useful in those procedures requiring minimally-invasive or endovascular access to remote tissue locations, where the instruments utilized must negotiate long, narrow, and tortuous pathways to the treatment site. In addition, many of the devices and systems of the invention are adapted to be reversible and removable from the patient at any point without interference with or trauma to internal tissues.

A sleeve is provided for placing over a flexible endoscope. The sleeve has a port between its distal and proximal openings and the port is connected to a vacuum source. Once the endoscope is retracted proximal to the suction port, the sleeve's proximal opening is sealed off and the entire sleeve is turned into a suction lumen. Devices and methods in accordance with the invention provide improvement in removing materials from body cavities, especially in removing stones from the upper urinary tract.

The invention discloses a mini-incision endoscope for diagnosis and treatment of upper urinary tract diseases, which is a novel ureter endoscope comprising an end flexible base 1, an operating grip 4, an operational key 3 for controlling the bending motion of the base end, since the main portion of the base of the end flexible ureter endoscope is of hard structure, whose end portion can be bent upwards or downwards by 180 degrees, the viewing field blind area and operation blind area of the hard ureter endoscope can be eliminated.

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances.

The invention discloses a medical auxiliary lithagogue system, which comprises a pedestal, a shedding tappet and a seat or a sickbed which are arranged on the pedestal, a vibration treatment device which is arranged on the seat or the sickbed and has a structure corresponding to the back curve of the human body or is arranged on the shedding tappet and has a structure corresponding to the foot bottom curve of the human body, a vibration driving mechanism driving the vibration treatment device to continuously vibrate in a preset vibration mode, and a control unit controlling and adjusting the vibration mode of the vibration driving mechanism and the state of a vibration switch. Both right and left sides of the seat or the sickbed or the upper front part of the shedding tappet is provided with a handrail. supporting components supporting the handrails and the handrails form a standing treatment device. The seat or the sickbed or the periphery of the shedding tappet is provided with a control panel connected with the control unit. The invention has reasonable design, simple and compact structure, low treatment cost, simple and convenient use, safe and reliable operation and good curative effect, makes up for defects in the existing upper urinary tract calculi treatment, and improves the treatment effect of the upper urinary tract calculi to a greater degree.

A Chinese medicine for treating the cough caused by upper respiratory tract inflammation is prepared from magnolia flower, liquorice root and xanthium fruit.

A novel ureteral stent used for drainage of a stoma of a ureter comprises an outer drainage part and an inner drainage part which are communicated with each other, wherein the inner drainage part adopts a tubular structure, and the outer drainage part adopts an eversible, folded and extended horn-shaped structure. The ureteral stent can effectively expand narrow ureter stoma, fully expand and support the lower ureter for urine drainage to effectively prevent upper urinary tract from infection and calculus generation, and bring convenience in stoma self-care of the patient; and related complication on the ureteral stent is obviously reduced, so as to greatly improve the life quality of the patient.

The invention provides a decoction for treating upper urinary tract calculi. The decoction consists of lysimachia christinae hance, lygodium japonicum, endothelium corneum gigeriae galli, herba pyrrosiae, plantain seeds, talcum, lalang grass rhizome, radix paeoniae alba, root of common peony, radix cyathulae, szechwan Chinaberry fruit, rhizoma corydalis and liquorice. The decoction for treating upper urinary tract calculi disclosed by the invention can clear away heat and toxic materials, promote diuresis and diminish inflammation, resolve tetany and relieve pain, and remove calculi; the decoction is free from toxic and harmful materials as well as side effect, and has no damage to kidney; and meanwhile, the decoction can nourish and protect the kidney, and prevent recurrence of urinary tract calculi.

The invention relates to a micro invasion endoscope of upper urinary tract disease diagnosis and treatment, which is a novel ureter endoscope formed by a terminal 2 of the bendable endoscope body, a rigid endoscope body 1 and operation keys 4 and 5 at the back of an operation handle 3. Most of the endoscope body is rigid structure, so the terminal of the endoscope is the same with the terminal of the traditional and soft ureter endoscope, which can be bended by 180 DEG C towards two opposite direction. The direction and angle of bending movement can be controlled by the operation key 4 at the back of the handle and operated conveniently. The invention has the advantages of the traditional ureter endoscope and soft ureter endoscope, is operated conveniently, no view and operation blind areas and the view is much clearer under the endoscope, which result in large improvement in the upper urinary tract disease diagnosis and treatment. While the operation key 5 can control relative sliding of the bendable endoscope body terminal and rigid endoscope body, so to reach the rigid structure of whole endoscope body during the endoscope entry process and protect the terminal of the soft endoscope body.

Disclosed is externally used fibrauretine liquid for gynaecology and oral cavity, wherein the preparation essentially comprises fibrauretine as active constituent, and balancing adjuvant and water for preparing the externally used liquid preparation, the fibrauretine is alkaloid extracted from natural plant of fibraurea stem, calculated by dried product, it comprises Palmatine Hydrochloride C21H21O.HCl 20-98%. The dosage type includes externally used liquid lotion or liniment, foam aerosol, ointment, gargle or spray.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres tothe urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The invention provides the use of a Shenshitong preparation for preparing medicine used for treating urinary infection, wherein the Shenshitong preparation is prepared by the following raw materials in weight ratio: 300-800 parts of loosestrife, 300-800 parts of friedsemen vaccariae, 200-500 parts of Herba Polygoni Avicularis, 100-250 parts of corydalis tuber processed by vinegar, 100-350 parts of heated chicken's gizzardskin, 100-350 parts of radix salviae miltiorrhizae, 50-200 parts of elecampane, 150-400 parts of fringed pink, 100-250 parts of radix achyranthis bidentatae, and 100-350 parts of climbing fern. The medicine in the invention is proved, by clinical tests and animal pharmacodynamic tests, to be capable of treating all urinary infections (infection of upper urinary tract: pyelonephritis, and infection of lower urinary tract: cystitis and urethritis), and have high efficiency. The medicine of the invention provides a new clinical medical choice.

The invention relates to medical instruments and discloses an upper urinary tract complex lesion percutaneous flexible ureteroscope operation to solve the problems that a flexible tube of an existing ureter device is prone to being left in a lower section of a ureter, a pump line is prone to disengaging, and consequently, body irrigation fluid leaks. According to the upper urinary tract complex lesion percutaneous flexible ureteroscope operation, a percutaneous puncturing and expanding device, a ureteroscope, a cold light source, a camera system, a bedside B ultrasonic machine, an intracavity calculus removing instrument, a high-pressure sacculus expander, a pressure adjusting water-delivery pump and a holmium laser ureteroscope are adopted. The ureteroscope comprises a sheathing canal, a flexible tube located in the sheathing canal, a push tube used for connecting the sheathing canal with the flexible tube, a handheld part located at the tail end of the sheathing canal and a washing valve. By means of the rotationally-combined sheathing canal and flexible tube, the ureteroscope is more suitable for being applied to complex kidney stone operations.

The invention locally delivers a chemotherapeutic or a radiographic contrast agent to an upper tract urothelial carcinoma (UTUC). The invention includes a balloon catheter with a working channel and aballoon placed into the ureter / renal pelvis via retrograde or antegrade ureteral access. The balloon is inflated to temporarily obstruct the ureter, and a formulation with a chemotherapeutic agent isinfused into the working channel of the catheter and allowed to dwell in the ureter / renal pelvis for a time sufficient to allow the formulation to adhere to and penetrate the urothelial wall. The formulations can be liposomal or non-liposomal formulations. At least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter / renal pelvis. The methods of the invention can be performed as an adjuvant therapy to other methods of treating UTUC, including ureteroscopic ablation or resection of the tumor.

The present invention discloses a kind of intravenous transfusion liquid and its preparation process. The intravenous transfusion liquid consists of chlorogenic acid 0.03-2.5 mg / ml, baicalin 0.1-4.0 mg / ml, isoosmotic regulator 5-10 mg / ml and pH regulator to regulate pH value to 4-9. It contains no forsythin and jasminoidin. The medicine has obvious curative effect on upper respiratory tract infection, pneumonia and viral respiratory tract infection.

Drug delivery devices and systems, are provided for delivery of a drug into the upper urinary tract of patients in need thereof. The drug delivery devices (100) may be deployed directly into the renal pelvis via a patient's ureter, bladder, and urethra, and the drug delivery devices can be wholly retained therein for local continuous, controlled release of a drug over an extended period.

The invention discloses an upper urinary tract integrated support drainage catheter and relates to medical instruments used for urinary tract drainage. The upper urinary tract integrated support drainage catheter comprises a fistulization tube and a connector. The fistulization tube comprises a short thin tube part in a pigtail coil shape, and a long thick tube part for drainage, wherein the long thick tube part is connected with the thin tube part. The joint of the thin tube part and the thick tube part is conical. The tail end can be bent, the long and thin end can be arranged in a ureter whole section, and the tail end is located in the urinary bladder. When the fistulization tube is pulled out, after the thick part of the fistulization tube leaves skin, the tail end of the long and thin part is still located in a collecting system. The upper urinary tract integrated support drainage catheter can drain an upper urinary tract, and the thin part is equivalent to a double J tube; during channel bleeding, bleeding stopping can be achieved through inflation air bags and traction compression; a drainage catheter can be slowly pulled out after a patient suffering from percutaneous renal stone breaking is in anesthetic awareness; in addition, the drainage tube can be tightly connected with the connector through a stepped structure, and no disengagement is likely to happen.

The invention discloses a method for culturing upper urinary tract urothelial cell carcinoma organoids. The method comprises the following steps: placing small upper urinary tract urothelial cell carcinoma tissue blocks in an inhibitor containing type II collagenase for first digestion treatment to obtain a first digest; placing the first digest in a pancreatin substitute containing an inhibitor, and performing second digestion treatment to obtain a second digest; sequentially performing first neutralization treatment, filtering treatment and centrifugal treatment on the second digest to obtain single cell precipitate; placing the single cell precipitate in a mixed substrate of a preset culture medium and substrate glue for resuspension treatment to obtain a gel suspension containing all cells; and culturing the gel suspension according to a preset scheme to obtain the upper urinary tract urothelial cell carcinoma organoids. According to the scheme, reliable clinical data can be provided for use of chemotherapeutic drugs and personalized treatment of upper urinary tract urothelial cell tumors.

The invention relates to methods for locally delivering a chemotherapeutic agent to an upper tract urothelial carcinoma (UTUC). The methods involve placing a balloon catheter that has a working channel and a balloon into the ureter / renal pelvis via retrograde or antegrade ureteral access; inflating the catheter balloon to temporarily obstruct the ureter; infusing (instilling) a liposomal formulation that includes a chemotherapeutic agent into the working channel of the catheter; and allowing the infused liposomal formulation to dwell in the ureter and / or renal pelvis for a time sufficient to allow at least a portion of the liposomal formulation to adhere to the urothelial wall. In the methods of the invention, at least a portion of the infused chemotherapeutic-agent formulation adheres to the urothelial wall while it is instilled and dwells in the ureter and / or renal pelvis. The disclosed methods can be performed as an adjuvant therapy to other methods of treating UTUC, such as ureteroscopic ablation or resection of the tumor.

The invention relates to a medicine inhalator, in particular to a medicine inhalation device for the upper respiratory tract. A T-branch pipe comprises a pipe (5), an air intake and exhaust pipe (6), an inverted-cone pipe (7) and a necking pipe (9). The inverted-cone pipe is arranged at the lower end of the pipe, the necking pipe is arranged at the lower end of the inverted-cone pipe, the air intake and exhaust pipe is arranged on one side of the pipe, and then the T-branch pipe is formed. A medicine inhalation pipe (8) is arranged on the lower portion of the necking pipe, a ball (3) is arranged in the inverted-cone pipe, and the lower end of an inhalation pipe (1) is connected with the upper end of the pipe in an inserted mode. According to the medicine inhalation device for the upper respiratory tract, the ball in the T-branch pipe is utilized to control powder to synchronously enter a nidus portion in the nasal cavity from the medicine inhalation pipe when a patient inhales, the ball closes the inverted-cone pipe communicated with the medicine inhalation pipe when the patient exhales, and therefore the purposes that breath is not affected and the powder is not wasted are achieved.

The invention belongs to the technical field of biomarkers, and discloses an upper urinary tract epithelium carcinoma (UTUC) diagnostic marker and application thereof, the upper urinary tract epithelium carcinoma diagnostic marker is DNA methylation biomarkers GDF15, TMEFF2 and VIM, the upper urinary tract epithelium carcinoma diagnostic marker is a DNA methylation biomarker, the upper urinary tract epithelium carcinoma diagnostic marker is a DNA methylation biomarker, the upper urinary tract epithelium carcinoma diagnostic marker is a DNA methylation biomarker, the upper urinary tract epithelium carcinoma diagnostic marker is a DNA methylation biomarker, and the upper urinary tract epithelium carcinoma diagnostic marker is a DNA methylation biomarker. The mRNA (messenger ribonucleic acid) sequence NM004864 of the GDF15 is shown as SEQ ID NO: 1; the mRNA (messenger ribonucleic acid) sequence NM001305134 of the TMEFF2 is as shown in SEQ ID NO: 2; the mRNA (messenger ribonucleic acid) sequence NM003380 of the VIM is shown as SEQ ID NO: 3. According to the method, the upper urinary tract epithelium cancer data are comprehensively mined from the multi-omics level, the biomarkers related to the upper urinary tract epithelium cancer are searched, the limitation of a traditional candidate gene method can be overcome, and the result accuracy is improved; clinical data are combined for integrated analysis, multiple biomarkers are jointly detected, a multi-index combined diagnosis model is established, and the diagnosis sensitivity and specificity are improved.

Problem: To provide a pharmaceutical composition for prevention or treatment of urinary track organ cancer. The composition does not cause a problem with respect to side effects, can be continually used for an extended period of time, and is administered to a urinary track organ by injection into a cavity of the urinary track organ. Solution: a solution configured to be injected into a cavity of a urinary track organ, the solution containing D-allose. The urinary track organ cavity is inside the upper urinary tract and inside the bladder. The solution is for injection therapy where the solution is injected into a cavity of a urinary track organ, and for utilization of increase in D-allose sugar intake into urinary track organ cancer cells (e.g. RT112, 253J, J82). The solution contains D-allose together with a pharmaceutically acceptable dilution agent or support. This pharmaceutical composition is for prevention or treatment of cancers in a urinary track organ.